Calira Therapeutics is Cambridge based biotech focused on allosteric inhibitors of CaMK2 for the treatment of diabetes and heart failure. By pursuing allosteric inhibition at a novel binding site identified by the Calira team, selective and safe inhibitors of CaMK2 can be advanced into the clinic.